Regenxbio Inc.
Clinical trials sponsored by Regenxbio Inc., explained in plain language.
-
One-Time gene therapy could slow duchenne muscular dystrophy
Disease control Recruiting nowThis trial tests a one-time gene therapy called RGX-202 for boys with Duchenne muscular dystrophy (DMD), a severe muscle-weakening disease. The therapy delivers a gene to help muscles produce a shortened but functional version of a key protein. The study involves about 65 boys ag…
Phase: PHASE2, PHASE3 • Sponsor: REGENXBIO Inc. • Aim: Disease control
Last updated May 26, 2026 07:55 UTC
-
Simple blood test could open door to gene therapy for duchenne boys
Knowledge-focused Recruiting nowThis study screens males with Duchenne muscular dystrophy (ages 0 to under 25) for antibodies against AAV8, a virus used in some gene therapies. The goal is to find out how many have these antibodies and identify those who might be eligible for future gene therapy trials. No trea…
Sponsor: REGENXBIO Inc. • Aim: Knowledge-focused
Last updated May 26, 2026 07:51 UTC